英科医疗(300677) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 17.45% to CNY 59,660,335.24 for the reporting period[7] - Operating revenue for the period was CNY 501,363,552.31, reflecting a 12.33% increase year-on-year[7] - Basic earnings per share increased by 6.60% to CNY 0.3037 for the reporting period[7] - The weighted average return on equity was 5.06%, down by 0.63% compared to the previous year[7] - Total operating revenue for the current period reached ¥501,481,414.08, an increase of 11.97% compared to ¥447,730,254.15 in the previous period[34] - Operating profit for the current period was ¥69,147,177.87, up from ¥59,903,769.59, reflecting a growth of 15.67%[35] - Net profit for the current period was ¥59,660,335.24, representing a 17.66% increase from ¥50,796,629.22 in the previous period[36] - The total comprehensive income for the current period was ¥59,848,542.69, up from ¥50,757,120.41, marking an increase of 17.83%[36] Assets and Liabilities - Total assets increased by 36.46% to CNY 2,262,903,329.98 compared to the end of the previous year[7] - Total liabilities rose to CNY 1,051,639,391.40 from CNY 570,726,387.27, an increase of about 84.0%[28] - Current assets rose to CNY 1,316,425,726.86, up from CNY 854,877,635.27, indicating a growth of about 54.2%[26] - Non-current assets totaled CNY 946,477,603.12, up from CNY 803,359,212.54, indicating an increase of about 17.8%[26] Cash Flow - The net cash flow from operating activities decreased by 37.59% to CNY 92,329,070.19 year-to-date[7] - Operating cash flow net amount decreased by 37.59% to RMB 92,329,070.19 from RMB 147,933,478.26, mainly due to reduced cash received from operating activities and increased tax payments[19] - The cash flow from operating activities was CNY 92,329,070.19, a decrease from CNY 147,933,478.26 in the previous period[48] - The company reported cash inflow from sales of goods and services amounting to ¥233,923,434.09, an increase from ¥207,279,277.26 in the previous year[53] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,351[11] - The largest shareholder, Liu Fangyi, holds 41.96% of the shares, totaling 82,435,560 shares[12] Expenses - The company reported a significant increase in management expenses by 44.65% to RMB 60,753,709.41 from RMB 41,999,669.23, mainly due to increased share-based payment expenses[19] - Research and development expenses increased to ¥18,330,334.81, up 19.06% from ¥15,403,664.50[34] Other Financial Metrics - Non-recurring gains and losses totaled CNY 8,290,332.85 for the reporting period[9] - The company did not report any overdue commitments or violations regarding external guarantees during the reporting period[21] - The company’s total assets impairment loss was ¥3,653,990.16, significantly higher than ¥292,863.29 in the previous period[35] Investment Activities - The total cash inflow from investment activities was ¥1,608,886,969.54, significantly higher than ¥530,910,000.00 in the previous year[50] - The total cash outflow for investment activities was ¥1,750,443,509.67, which is an increase from ¥894,954,322.18 in the previous year, reflecting a rise of 95.5%[50]